CVKD | Cadrenal Therapeutics, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	17.48 - 18.25
52 Week Range	5.40 - 22.90
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	20,401
Average Volume	44,147
Shares Outstanding	1,879,710
Market Cap	33,139,287
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-01-20

Valuation
Profitability
Growth
Health
P/E Ratio	-2.02
Forward P/E Ratio	N/A
EPS	-8.73
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	CVKD

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

CVKD's peers: BRTX, CMMB, EQ, GTBP, ICCC, LCTX, MDXG, PPBT, SABS, SPRC, TTNP, OKYO, SNTI, MLEC, MLYS, GPCR, CNTA, NVCT, ZIVO, FHTX, QNRX, IKNA, ENOB, ELYM, HCWB, XCUR, CINGW, ANEB, MNPR, ANTX, MIRO, IKT, PMVP

*Chart delayed

Analyzing fundamentals for CVKD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CVKD Fundamentals page.

Watching at CVKD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CVKD Technicals page.